Notably, our ZNF154 methylation detection method achieved 100% sensitivity and 80% specificity when used on plasma from patients with early-stage pancreatic adenocarcinoma, encouraging future studies to validate its effectiveness in early stage tumors. The gene discussed is ZNF154; the disease is pancreatic adenocarcinoma.